Mosaic Biosciences generated $25 million in revenue during the second quarter of 2026 and is on track to double its full-year 2025 sales, underscoring the growing role of biological crop nutrition in The Mosaic Company’s strategy to diversify beyond traditional phosphate fertilizers.
Speaking during Mosaic’s second-quarter earnings call , CEO Bruce Bodine said the Biosciences business is delivering both commercial value to growers and an expanding contribution to the company. The division launched five new products during the first half of 2026, taking its active portfolio to more than a dozen formulations designed to improve nutrient uptake, strengthen soil biology and enhance plant tolerance to environmental stress.
“We see biologicals as a fundamental complement to our mineral nutrition portfolio,” Bodine said. The performance comes as Mosaic’s core phosphate business faces a more challenging cost environment. The company reported a $273 million net loss in the second quarter, with sulfur-related cost inflation weighing on its phosphate operations.
Against that backdrop, Biosciences offers Mosaic a potentially attractive growth engine, combining biological crop inputs with a relatively lower-capital operating model. The division is increasingly central to the company’s broader effort to diversify earnings and expand its position in integrated crop nutrition.
New products launched in the first half of 2026 include solutions for corn starter programs, soybean inoculants and micronutrient blends designed to improve phosphate availability in the root zone. Mosaic Biosciences has also expanded its development pipeline through a partnership with Elicit Plant focused on biological solutions for water-stressed canola crops in North America.
The business is leveraging Mosaic’s established retail and wholesale distribution network, allowing its biological products to reach growers across the Americas without requiring the company to build a separate sales infrastructure.
While Mosaic has not disclosed a standalone revenue target for Biosciences, the company has indicated that biologicals could become a material contributor to earnings by 2028. Mosaic’s strategy reflects a broader shift across the agricultural inputs industry, where major fertilizer and crop-protection companies are increasingly investing in biological technologies as growers seek tools that can improve nutrient efficiency, soil health and crop resilience.
BASF, Corteva and Syngenta have all acquired or invested in biological platforms in recent years, highlighting the intensifying competition for a share of the rapidly expanding biologicals market.
For Mosaic, the opportunity lies in integrating biologicals with its established mineral nutrition portfolio rather than positioning the technologies as substitutes. If the Biosciences division sustains its current growth trajectory, biological crop nutrition could become an increasingly important pillar of Mosaic’s portfolio—and a meaningful source of earnings diversification by the end of the decade.
